Diligence memo · auto-generated · as of July 2, 2026

Fervent Pharmaceuticals Llc

Fervent Pharmaceuticals Llc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Fervent Pharmaceuticals Llc operates in Pharmaceuticals, based in Greenville.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Fervent Pharmaceuticals Llc has raised $200K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $200K on 2014-04-14.

Most recent recorded round closed around 2014-04-14.

Valuation (modeled)modeled

Provath models Fervent Pharmaceuticals Llc at approximately $9.5M (range $112K–$107M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.83× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era. Within the normal band (83% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 12.2 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 5% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 17% of those peers.

Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.